Vera Therapeutics (VERA) director awarded options on 17,084 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vera Therapeutics director Kimball Hall received a grant of stock options covering 17,084 shares of Class A common stock at an exercise price of $34.35 per share. These options expire on May 20, 2036 and are held directly.
The options will vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting, provided Hall remains in continuous service. They will also vest in full upon a change in control, again contingent on continuous service through that date.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Hall Kimball
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 17,084 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 17,084 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Option grant size: 17,084 options
Exercise price: $34.35 per share
Underlying shares: 17,084 shares
+2 more
5 metrics
Option grant size
17,084 options
Stock Option (right to buy) granted to director Kimball Hall
Exercise price
$34.35 per share
Conversion or exercise price for underlying Class A common stock
Underlying shares
17,084 shares
Class A Common Stock underlying the stock option grant
Expiration date
May 20, 2036
Option expiration date for the granted stock options
Options held after grant
17,084 options
Total derivative securities following the reported transaction
Key Terms
Stock Option (right to buy), Class A Common Stock, change in control, continuous service, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
Class A Common Stock financial
"underlying_security_title: Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
change in control financial
"the shares will vest in full upon a change in control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
continuous service financial
"subject to the Reporting Person's continuous service through such vesting date"
annual stockholder meeting financial
"the date of the Company's 2027 annual stockholder meeting"
An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.
FAQ
What insider transaction did Vera Therapeutics (VERA) report in this Form 4?
Vera Therapeutics reported a stock option grant to director Kimball Hall for 17,084 shares of Class A common stock. The options are compensation-related, not an open-market purchase or sale, and give the right to buy shares at a fixed price if they vest.
How many Vera Therapeutics (VERA) options did Kimball Hall receive and at what price?
Kimball Hall received stock options for 17,084 underlying shares at an exercise price of $34.35 per share. This grant gives the director the potential to buy those shares at that fixed price if the vesting conditions are met before the options expire.
When do Kimball Hall’s Vera Therapeutics (VERA) stock options vest?
The stock options vest in full on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockholder meeting. Vesting requires Hall’s continuous service through that date, aligning the grant with ongoing board service and company governance milestones.
What happens to Kimball Hall’s Vera Therapeutics (VERA) options if there is a change in control?
All 17,084 options vest in full upon a change in control, provided Hall remains in continuous service through the change-in-control date. This accelerates vesting, ensuring the director’s compensation recognizes a significant corporate event such as a merger or acquisition impacting Vera Therapeutics.
When do Kimball Hall’s Vera Therapeutics (VERA) stock options expire?
The granted stock options expire on May 20, 2036, setting a long-term window to exercise once vested. After that expiration date, any unexercised options become worthless, so value realization depends on vesting, continuous service, and future share price relative to the $34.35 exercise price.